| Commercial name | Active substance | Indication | |
|---|---|---|---|
| Norditropin® | somatotropin | growth failure in children with achondroplasia/hypochondroplasia | |
| Sparsentan | Sparsentan | Treatment in adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1g/day | |